Last edition
News about "Preclinical Oral Proteolysis-Targeting Chimera"
Pathos AI, AstraZeneca Partner to Advance AI-Driven Breast Cancer Therapy into Clinical Development
Pathos AI and AstraZeneca have entered a strategic collaboration to advance AZD4241, an investigational therapy for ER+/HER2- breast cancer, using artificial intelligence to enhance clinical development and precision oncology.
Preclinical Oral Proteolysis-Targeting Chimera | 05/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members